Advertisement

Advertisement

MTVA Stock Latest News

MetaVia: Buy Rating Reiterated as Synergistic Cardiometabolic Pipeline Supports Unchanged $8 Price Target

RatingsMetaVia: Buy Rating Reiterated as Synergistic Cardiometabolic Pipeline Supports Unchanged $8 Price Target

MetaVia Shareholders Approve Equity Plan and Reverse Split

PremiumCompany Announcements

MetaVia Shareholders Approve Equity Plan and Reverse Split

5d ago

MetaVia highlights obesity and metabolic pipeline advancements

PremiumCompany Announcements

MetaVia highlights obesity and metabolic pipeline advancements

5d ago

MetaVia presents data at ADA supporting DA-1726, vanoglipel

PremiumThe Fly

MetaVia presents data at ADA supporting DA-1726, vanoglipel

5d ago

Fein Reiterates Buy on MetaVia as New Phase 1 Liver Data De-Risk DA-1726 and Support Unchanged $20 Price Target

PremiumRatings

Fein Reiterates Buy on MetaVia as New Phase 1 Liver Data De-Risk DA-1726 and Support Unchanged $20 Price Target

16d ago

MetaVia’s DA-1726 shows efficacy in obesity and MASH presentations

PremiumThe FlyMetaVia’s DA-1726 shows efficacy in obesity and MASH presentations

17d ago

MetaVia highlights promising Phase 1 obesity drug data

Company Announcements

MetaVia highlights promising Phase 1 obesity drug data

17d ago

3 Penny Stocks to Watch Now, 5/21/26

Market News

3 Penny Stocks to Watch Now, 5/21/26

23d ago

Analyst Reiterates Buy on MetaVia, Maintains $8 Price Target Amid Promising Metabolic Pipeline and Upcoming Data Catalysts

PremiumRatings

Analyst Reiterates Buy on MetaVia, Maintains $8 Price Target Amid Promising Metabolic Pipeline and Upcoming Data Catalysts

23d ago

Fein Reiterates Buy on MetaVia, Keeps DA-1726-Driven Price Target Unchanged at $20

PremiumRatings

Fein Reiterates Buy on MetaVia, Keeps DA-1726-Driven Price Target Unchanged at $20

26d ago

MetaVia Showcases Key Cardiometabolic Data at ADA 2026

PremiumCompany Announcements

MetaVia Showcases Key Cardiometabolic Data at ADA 2026

26d ago

MetaVia Highlights Strong DA-1726 Phase 1 Weight-Loss Data

PremiumCompany Announcements

MetaVia Highlights Strong DA-1726 Phase 1 Weight-Loss Data

1M ago

MetaVia to Present New DA-1726 Obesity Data at EASL

PremiumCompany AnnouncementsMetaVia to Present New DA-1726 Obesity Data at EASL

1M ago

MetaVia Advances DA-1726 Obesity Trial With First Patient

Company Announcements

MetaVia Advances DA-1726 Obesity Trial With First Patient

2M ago

MetaVia says first patient dosed in Part 3 of Phase 1 trial of DA-1726

The Fly

MetaVia says first patient dosed in Part 3 of Phase 1 trial of DA-1726

2M ago

MetaVia (MTVA): Differentiated Dual-Agonist Obesity Therapy and Solid Cash Runway Underpin Buy Rating

PremiumRatings

MetaVia (MTVA): Differentiated Dual-Agonist Obesity Therapy and Solid Cash Runway Underpin Buy Rating

2M ago

PremiumRatings

Maintaining Buy on MetaVia: Advancing DA-1726 Clinical Profile and Differentiated Obesity/MASH Strategy Despite Reduced Target Price

3M ago

MetaVia Updates Investor Strategy for Obesity and MASH

PremiumCompany Announcements

MetaVia Updates Investor Strategy for Obesity and MASH

3M ago

MetaVia: Cash position adequate to fund operations into 4Q26

PremiumThe Fly

MetaVia: Cash position adequate to fund operations into 4Q26

3M ago

MetaVia CEO says ‘significant progress advancing our cardiometabolic portfolio’

PremiumThe FlyMetaVia CEO says ‘significant progress advancing our cardiometabolic portfolio’

3M ago

Metavia Inc. (MTVA) Q4 Earnings Cheat Sheet

Pre-Earnings

Metavia Inc. (MTVA) Q4 Earnings Cheat Sheet

3M ago

MetaVia Advances DA-1726 Obesity Drug into Phase 1 Part 3

Company Announcements

MetaVia Advances DA-1726 Obesity Drug into Phase 1 Part 3

3M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >